Suppr超能文献

制备和评价四苯嗪对映体和二氢四苯嗪的全部 8 种立体异构体作为 VMAT2 抑制剂。

Preparation and evaluation of tetrabenazine enantiomers and all eight stereoisomers of dihydrotetrabenazine as VMAT2 inhibitors.

机构信息

Center for Drug Discovery, College of Pharmacy, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, China.

出版信息

Eur J Med Chem. 2011 May;46(5):1841-8. doi: 10.1016/j.ejmech.2011.02.046. Epub 2011 Feb 23.

Abstract

Tetrabenazine (TBZ) ((±)-1) and dihydrotetrabenazines (DHTBZ) are potent inhibitors of VMAT2. Herein, a practical chemical resolution of (±)-1 and stereoselective synthesis of all eight DHTBZ stereoisomers are described. The result of VMAT2 binding assay revealed that (+)-1 (Ki=4.47 nM) was 8000-fold more potent than (-)-1 (Ki=36,400 nM). Among all eight DHTBZ stereoisomers, (2R,3R,11bR)-DHTBZ ((+)-2: Ki=3.96 nM) showed the greatest affinity for VMAT2. The (3R,11bR)-configuration appeared to play a key role for VMAT2 binding. In summary, (+)-1, (+)-2, and their derivatives warrant further studies in order to develop more potent and safer drugs for the treatment of chorea associated with Huntington's disease and other hyperkinetic disorders.

摘要

四苯嗪(TBZ)((±)-1)和二氢四苯嗪(DHTBZ)是 VMAT2 的强效抑制剂。本文描述了(±)-1 的实用化学拆分和所有八种 DHTBZ 立体异构体的立体选择性合成。VMAT2 结合测定的结果表明,(+)-1(Ki=4.47 nM)的活性比(-)-1(Ki=36,400 nM)高 8000 倍。在所有八种 DHTBZ 立体异构体中,(2R,3R,11bR)-DHTBZ((+)-2:Ki=3.96 nM)对 VMAT2 具有最大的亲和力。(3R,11bR)-构型似乎对 VMAT2 结合起关键作用。总之,(+)-1、(+)-2 及其衍生物值得进一步研究,以便开发更有效和更安全的药物,用于治疗亨廷顿病和其他运动障碍相关的舞蹈症。

相似文献

6
VMAT2 inhibitors for the treatment of hyperkinetic movement disorders.VMAT2 抑制剂治疗多动性运动障碍。
Pharmacol Ther. 2020 Aug;212:107580. doi: 10.1016/j.pharmthera.2020.107580. Epub 2020 May 23.
8
Deutetrabenazine for the treatment of Huntington's chorea.曲美他嗪治疗亨廷顿舞蹈病。
Expert Rev Neurother. 2018 Aug;18(8):625-631. doi: 10.1080/14737175.2018.1500178. Epub 2018 Jul 17.

引用本文的文献

9
VMAT2 Inhibitors in Neuropsychiatric Disorders.VMAT2 抑制剂在神经精神疾病中的应用。
CNS Drugs. 2018 Dec;32(12):1131-1144. doi: 10.1007/s40263-018-0580-y.

本文引用的文献

2
Tetrabenazine.泰必利嗪。
Expert Opin Pharmacother. 2009 Dec;10(17):2883-96. doi: 10.1517/14656560903386292.
4
Treatment of hyperkinetic movement disorders.多动性运动障碍的治疗。
Lancet Neurol. 2009 Sep;8(9):844-56. doi: 10.1016/S1474-4422(09)70183-8.
6
Emerging drugs in Tourette syndrome.图雷特综合征的新兴药物
Expert Opin Emerg Drugs. 2005 May;10(2):365-80. doi: 10.1517/14728214.10.2.365.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验